A cross-party group of members of Parliament has urged the National Health Service to significantly increase access to the weight-loss medication Mounjaro in England, arguing that current plans fall short of public health needs.
The Health Committee characterized the existing rollout plan covering 220,000 people in 2028 as inadequate, representing only around 6% of eligible individuals. This limited availability has contributed to the emergence of a two-tier system in which wealthier patients can readily access weight-loss medications through private channels, while others face barriers to treatment. More than a million people have reportedly sought private prescriptions for Mounjaro and Wegovy, the committee noted.
The financial considerations present a significant barrier to expanded NHS provision. Providing the medication to all 2.8 million eligible people immediately would cost the NHS £15.2 billion over five years, according to estimates cited by the committee. The NHS is currently pursuing a 12-year rollout schedule, though this approach is under review. MPs suggested that costs could be reduced through operational improvements, including greater use of digital platforms similar to those employed by private providers, rather than relying heavily on general practitioners for monitoring and oversight.
The committee emphasized broader concerns about obesity treatment infrastructure, calling the existing weight-loss services poorly designed and inadequately resourced. Recommendations include expanded access to diet and lifestyle support programs and bariatric surgery options. MPs also highlighted the black market for unlicensed weight-loss medications, calling for public awareness campaigns and regulatory reviews addressing online advertising.
NHS England responded by stating it is exploring acceleration of the weight-loss drug rollout while continuing to prioritize patients with the most severe and complex needs.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI